Physica Medica: European Journal of Medical Physics
Volume 26, Issue 2 , Pages 71-79 , April 2010

Possibility of limiting the un-justified irradiation in 131I therapy of Graves' disease: A thyroid mass-reduction based method for the optimum activity calculation

  • Antonio C. Traino

      Affiliations

    • Sezione di Fisica Medica, U.O.Fisica Sanitaria, Azienda Ospedaliero-Universitaria Pisana, via Roma 67, I56125 Pisa, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 050 992219; fax +39 050 992513.
    • ,
  • Mariano Grosso

      Affiliations

    • Centro Regionale di Medicina Nucleare, Azienda Ospedaliero-Universitaria Pisana e Università di Pisa, via Roma 67, I56125 Pisa, Italy
    • ,
  • Giuliano Mariani

      Affiliations

    • Centro Regionale di Medicina Nucleare, Azienda Ospedaliero-Universitaria Pisana e Università di Pisa, via Roma 67, I56125 Pisa, Italy

Received 1 April 2009 ,Revised 28 June 2009 ,Accepted 29 August 2009.

References 

  1. Sisson JC, Avram AM, Rubello D, Gross MD. Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?. Eur J Nucl Med Mol Imaging. 2007;34:1129–1130
  2. van Isselt JW, de Klerk JMH, Lips CJM. Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?. Eur J Nucl Med Mol Imaging. 2007;34:1183–1184
  3. Thomas SR. Options for radionuclide therapy: from fixed activity to patient-specific treatment planning. Cancer Biother Radiopharm. 2002;17:71–82
  4. Catargi B, Leprat F, Guyot M, Valli M, Ducassou D, Tabarin A. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and other possible factors affecting outcome. Eur J Endocrinol. 1999;141:117–121
  5. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves' hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid. 1997;7:247–251
  6. Jönsson H, Mattsson S. Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism. Rad Prot Dosim. 2004;108:107–114
  7. Peters H, Fischer C, Bogner U, Schleusener H. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131-I activity. Results from a prospective, randomised, multicentre study. Eur J Clin Invest. 1995;25:186–193
  8. Reinhardt MJ, Brink I, Joe AY, von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy in Graves' disease based on tissue absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med. 2002;29:1118–1124
  9. Bajnok L, Mezosi E, Nagy E, Szabo J, Sztojka I, Varga J, et al. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary?. Thyroid. 1999;9:865–869
  10. Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves' disease. A clinical outcome study. Eur J Nucl Med. 2001;28:1489–1495
  11. Muratami Y, Takamatsu J, Sakane S, Kuma K, Ohshawa N. Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid stimulating antibody and treatment outcome. J Clin Endocrinol Metab. 1996;81:3257–3260
  12. Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid stimulating and thyrotropin blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998;83:40–46
  13. Haase A, Bahre M, Lauer I, Meller B, Richter E. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose. Exp Clin Endocrinol Diabetes. 2000;108:133–137
  14. Gomez-Arnaiz N, Andia E, Guma A, Abos R, Soler J, Gomez JM. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism. Horm Metab Res. 2003;35:492–497
  15. Di Martino F, Traino AC, Brill AB, Stabin MG, Lazzeri M. A theoretical model for prescription of the patient-specific therapeutic activity for radioiodine therapy of Graves' disease. Phys Med Biol. 2002;47:1493–1499
  16. Traino AC, Di Martino F, Grosso M, Monzani F, Dardano A, Caraccio N, et al. A predictive mathematical model for calculation of the final mass of Graves' disease thyroids treated with 131I. Phys Med Biol. 2005;50:2181–2191
  17. Traino AC, Xhafa B. Accuracy of two simple methods for estimation of thyroidal 131I kinetics for dosimetry-based treatment of Graves' disease. Med Phys. 2009;36:1212–1218
  18. Traino AC, Di Martino F, Grosso M, Monzani F, Dardano A, Caraccio N, et al. A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper. Nucl Med Commun. 2006;27:439–446
  19. Stabin MG, et al. In:  Hankin RE editors. Internal radiation dosimetry in nuclear medicine vol.I. 1996;(Mosby, St Louis), pp.316–333
  20. Traino AC, Di Martino F, Lazzeri M. A dosimetric approach to patient specific radioiodine treatment of Graves' disease with incorporation of treatment induced changes in thyroid mass. Med Phys. 2004;31:2121–2127
  21. Szebeni A, Beleznay E. New simple method for thyroid volume determination by ultrasonography. J Clin Ultrasound. 1992;20:329–339
  22. Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer. 2007;109:1972–1979
  23. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007;92:2190–6
  24. Council Directive 97/43/EURATOM on health protection of individuals against the dangers of ionizing radiation in relation to medical exposure, and repealing directive 84/466/EURATOM, (June 1997). http://ac.europe.eu/energy/nuclear/radioprotection/doc/legislation/9743_eu.pdf.
  25. Vanderpump M. Cardiovascular and cancer mortality after radioiodine treatment of hyperthyroidism. J Clin Endocrinol Metab. 2007;92:2033–2035
  26. Lucignani G. Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new?. Eur J Nucl Med Mol Imaging. 2007;34:1504–1509

PII: S1120-1797(09)00051-9

doi: 10.1016/j.ejmp.2009.08.003

Physica Medica: European Journal of Medical Physics
Volume 26, Issue 2 , Pages 71-79 , April 2010

Article Tools

* Image Usage & Resolution